Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.73 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.73 |
| ▸ | HPGD | P15428 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.73 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.73 |
| ▸ | FAAH | O00519 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.73 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345339 | 1.00 | GABRA1 (0.73) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Propofol SCHEMBL21412347 | 0.93 | GABRA1 (0.77) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Phenol SCHEMBL11288642 | 0.90 | GABRA1 (0.59) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| P-Cymene SCHEMBL25285947 | 0.87 | GABRA1 (0.55) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| SCHEMBL921042 | 0.86 | ALDH1A1 (0.59) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Propofol SCHEMBL2414429 | 0.85 | GABRA1 (1.00) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Propofol SCHEMBL36245 | 0.85 | GABRA1 (1.00) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Isothymol SCHEMBL17423985 | 0.84 | LMNA (0.52) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| SCHEMBL23250717 | 0.83 | GABRA1 (0.61) | GABRA1GABRB2HPGDCYP1A2CYP3A4 | |
| Propofol SCHEMBL13729728 | 0.83 | CYP1A2 (0.68) | GABRA1GABRB2HPGDCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192215-A | Process for preparing phenol products from 2, 4-xylenol/2, 5-xylenol | 陕西巴斯腾科技有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-119798687-A | Modified acrylic polyester resin applied to silver reflecting film and coating thereof | 上海利圆升科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| EP-3724193-B1 | PROCESS FOR PREPARING 2-EXO-(2-METHYLBENZYLOXY)-1-METHYL-4-ISOPROPYL-7-OXABICYCLO[2.2.1]HEPTANE | BASF AGRO BV (NL) | 2024-09-11 | — | — | EP | claimed |
| US-11897895-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicy-clo[2.2.1]heptane | BASF Agro B.V. (NL) | 2024-02-13 | — | — | US | claimed |
| US-20230363380-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2023-11-16 | — | — | US | claimed |
| CN-115843953-A | Antibacterial composition and preparation method and application thereof | 珠海市自然之旅生物技术有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-114272323-A | Traditional Chinese medicine formula for regulating and controlling intestinal function of lactating women | 华子昂 | 2022-04-05 | — | — | CN | claimed |
| US-20220079145-A1 | INSTRINSICALLY ANTIMICROBIAL POROSIC MATRIX COMPOSITES AND METHOD OF MANUFACTURE THEREOF | WILSON JOHN PAUL (US) | 2022-03-17 | — | — | US | claimed |
| CN-113512232-A | Macromolecular hindered phenol antioxidant and preparation method and application thereof | 中国石油天然气股份有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-112970790-A | Preparation method of synergist based on environment-friendly mosquito repellent aerosol | 深圳馥稷生物科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-20020103261-A1 | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals | VAN BEEK GLOBAL, LLC | 2002-08-01 | — | — | US | claimed |
| US-6414036-B1 | MIXTURE OF PHENOLIC DRUG AND CARRIER | VAN BEEK GLOBAL/NINKOV LLC | 2002-07-02 | — | — | US | claimed |
| EP-1207865-A1 | COMPOSITION FOR TREATMENT OF INFECTIONS OF HUMANS AND ANIMALS | Van Beek Global/Ninkov L.L.C. (US) | 2002-05-29 | — | — | EP | claimed |
| WO-2002028382-A1 | COMPOSITIONS FOR INJECTION OR INTRAVENOUS ADMINISTRATION FOR THE TREATMENT OF INTERNAL INFECTION OR INFLAMMATION IN HUMANS AND ANIMALS | VAN BEEK, RON (US) | 2002-04-11 | — | — | WO | claimed |
| WO-2001015680-A1 | COMPOSITION FOR TREATMENT OF INFECTIONS OF HUMANS AND ANIMALS | VAN BEEK GLOBAL/NINKOV L.L.C. (US) | 2001-03-08 | — | — | WO | claimed |
| CN-1229362-A | Wound covering material containing silk fibroin and silk sericin as main components and process for producing the same | JP NATIONAL INST OF SECRICLTUR (JP) | 1999-09-22 | — | — | CN | claimed |
| EP-0670843-B1 | ALPHA CRYSTALLINE MODIFICATION OF 2,2',2\"-NITRILO TRIETHYL-TRIS-(3,3',5,5'-TETRA-TERT-BUTYL-1,1'-BIPHENYL-2,2'-DIYL)PHOSPHITE] | CIBA GEIGY AG (CH) | 1997-02-26 | — | — | EP | claimed |
| EP-0670842-B1 | BETA CRYSTALLINE MODIFICATION OF 2,2',2''-NITRILO TRIETHYL-TRIS-(3,3',5,5'-TETRA-TERT-BUTYL-1,1'-BIPHENYL-2,2'-DIYL) PHOSPHITE] | CIBA GEIGY AG (CH) | 1997-01-22 | — | — | EP | claimed |
| EP-0380052-B1 | Process for preparing alkyl halogenides | SUMITOMO CHEMICAL CO (JP) | 1994-04-13 | — | — | EP | claimed |
| US-5043379-A | Vinyl chloride polymer; plasticizer; aromatic diisocyanate polymer to increase adhesiveness; thermal dissociation promoting agent | KYPEISHA CHEMICAL CO., LTD. (JP) | 1991-08-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897895-B2 | Process for preparing 2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicy-clo[2.2.1]heptane | EXOC1, EXOC4, EXOC3 | GABRA1 1539/4885GABRB2 609/4885HPGD 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.